Trial · NCT03444870
Adverse events1,374
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,374
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Arrhythmia | Cardiac disorders | Global - DBT Period: Placebo | 1 | 481 | 1 |
| other | Arrhythmia | Cardiac disorders | Global - DBT Period: Gantenerumab | 0 | 503 | 0 |
| other | Arrhythmia | Cardiac disorders | China Extension - DBT Period: Placebo | 0 | 33 | 0 |
| other | Arrhythmia | Cardiac disorders | China Extension - DBT Period: Gantenerumab | 0 | 35 | 0 |
| other | Arrhythmia | Cardiac disorders | Global - OLE Period: Placebo (DBT) to Gantenerumab | 0 | 9 | 0 |
| other | Arrhythmia | Cardiac disorders | Global - OLE Period: Gantenerumab (DBT) to Gantenerumab | 2 | 20 | 3 |
| other | Cardiac failure chronic | Cardiac disorders | Global - DBT Period: Placebo | 1 | 481 | 1 |
| other | Cardiac failure chronic | Cardiac disorders | Global - DBT Period: Gantenerumab | 0 | 503 | 0 |
| other | Cardiac failure chronic | Cardiac disorders | China Extension - DBT Period: Placebo | 0 | 33 | 0 |
| other | Cardiac failure chronic | Cardiac disorders | China Extension - DBT Period: Gantenerumab | 0 | 35 | 0 |
| other | Cardiac failure chronic | Cardiac disorders | Global - OLE Period: Placebo (DBT) to Gantenerumab | 1 | 9 | 1 |
| other | Cardiac failure chronic | Cardiac disorders | Global - OLE Period: Gantenerumab (DBT) to Gantenerumab | 0 | 20 | 0 |
| other | Myocardial ischaemia | Cardiac disorders | Global - DBT Period: Placebo | 1 | 481 | 1 |
| other | Myocardial ischaemia | Cardiac disorders | Global - DBT Period: Gantenerumab | 0 | 503 | 0 |
| other | Myocardial ischaemia | Cardiac disorders | China Extension - DBT Period: Placebo | 0 | 33 | 0 |
| other | Myocardial ischaemia | Cardiac disorders | China Extension - DBT Period: Gantenerumab | 0 | 35 | 0 |
| other | Myocardial ischaemia | Cardiac disorders | Global - OLE Period: Placebo (DBT) to Gantenerumab | 1 | 9 | 1 |
| other | Myocardial ischaemia | Cardiac disorders | Global - OLE Period: Gantenerumab (DBT) to Gantenerumab | 0 | 20 | 0 |
| other | Diarrhoea | Gastrointestinal disorders | Global - DBT Period: Placebo | 26 | 481 | 29 |
| other | Diarrhoea | Gastrointestinal disorders | Global - DBT Period: Gantenerumab | 33 | 503 | 48 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03444870/events